论文部分内容阅读
目的:研究新的耐药相关基因TCRP1在口腔鳞癌组织中的表达及其与顺铂临床疗效的关系,同时对TCRP1的作用机制进行初步探索。方法:采用免疫组织化学法检测TCRP1在舌癌组织中的表达及其与临床顺铂化学治疗疗效之间及体外药敏实验的相关性,Western印迹法及免疫共沉淀甄别TCRP1下游的作用分子。结果:在TCRP1低表达的患者中,缓解率达84.62%,而高表达患者组中缓解率为37.5%。体外药敏结果显示类似的结果。TCRP1表达改变影响Akt信号通路分子的表达,而且TCRP1与Akt存在物理上的相互结合。结论:TCRP1的表达影响口腔鳞癌的顺铂化学治疗疗效。TCRP1介导顺铂耐药的作用机制至少部分与TCRP1对Akt信号通路调节有关。
Objective: To study the expression of TCRP1 in oral squamous cell carcinoma and its relationship with the clinical efficacy of cisplatin, and to explore the mechanism of TCRP1. Methods: The expression of TCRP1 in tongue cancer tissues was examined by immunohistochemistry. The correlation between the chemotherapeutic efficacy of Cisplatin and drug susceptibility in vitro was detected by Western blotting and co-immunoprecipitation to identify the downstream molecules of TCRP1. Results: In patients with low expression of TCRP1, the remission rate was 84.62%, while the remission rate was 37.5% in patients with high expression of TCRP1. In vitro susceptibility results show similar results. TCRP1 expression changes affect the expression of Akt signaling molecules, and TCRP1 and Akt physically interact with each other. Conclusion: The expression of TCRP1 affects the efficacy of cisplatin chemotherapy in oral squamous cell carcinoma. The mechanism of TCRP1-mediated cisplatin resistance is at least partly related to the regulation of Akt signaling by TCRP1.